Immunotherapy Oncology Clinical Trials Medical Research Cell Biology Cancer Treatment Medical Treatments Cancer Patient Care Immunology
Penn researchers report 81% response rates and durable remissions in refractory B-cell lymphoma using huCART19-IL18, a next-generation CAR T therapy with a rapid manufacturing process.